BRCA1 and breast cancer: Traditionally genetic testing to estimate increased lifetime risk of breast cancer (BC) has focused on pathogenic (as opposed to benign) variants in the genes BRCA1 and BRCA2. The development of new genetic technologies allows the identification of several breast cancer predisposition genes (gene-panels).